🇺🇸 Tick-Borne Encephalitis vaccine in United States

43 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Oligohydramnios — 9 reports (20.93%)
  2. Exposure During Pregnancy — 6 reports (13.95%)
  3. Covid-19 — 4 reports (9.3%)
  4. Fatigue — 4 reports (9.3%)
  5. Live Birth — 4 reports (9.3%)
  6. Maternal Exposure During Pregnancy — 4 reports (9.3%)
  7. Drug Ineffective — 3 reports (6.98%)
  8. Lymphocyte Count Decreased — 3 reports (6.98%)
  9. Neutrophil Count Decreased — 3 reports (6.98%)
  10. Urinary Tract Infection — 3 reports (6.98%)

Source database →

Tick-Borne Encephalitis vaccine in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Tick-Borne Encephalitis vaccine approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Tick-Borne Encephalitis vaccine in United States?

Novartis is the originator. The local marketing authorisation holder may differ — check the official source linked above.